The estimated Net Worth of Michael Kauffman is at least $16 Milion dollars as of 28 February 2022. Michael Kauffman owns over 12,452 units of Karyopharm Therapeutics Inc stock worth over $664,617 and over the last 12 years he sold KPTI stock worth over $12,111,087. In addition, he makes $3,231,500 as Co-Founder i Chief Executive Officer and Director at Karyopharm Therapeutics Inc.
Michael has made over 60 trades of the Karyopharm Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 12,452 units of KPTI stock worth $127,508 on 28 February 2022.
The largest trade he's ever made was selling 200,000 units of Karyopharm Therapeutics Inc stock on 2 July 2014 worth over $8,500,000. On average, Michael trades about 10,792 units every 30 days since 2012. As of 28 February 2022 he still owns at least 898,131 units of Karyopharm Therapeutics Inc stock.
You can see the complete history of Michael Kauffman stock trades at the bottom of the page.
Dr. Michael G. Kauffman M.D., Ph.D. serves as Co-Founder, Chief Executive Officer and Director of the Company. He serves as Co-Founder, Chief Executive Officer and Director of the Company. serves as Co-Founder, Chief Executive Officer and Director of the Company. serves as Co-Founder, Chief Executive Officer and Director of the Company. Dr. Kauffman co-founded Karyopharm with Dr. Sharon Shacham in 2008 and served as our President from January 2011 to December 2013 and as Chief Medical Officer from December 2012 to December 2013. Prior to joining Karyopharm, he was Chief Medical Officer of Onyx Pharmaceuticals Inc., a biopharmaceutical company, from November 2009 to December 2010. From November 2008 to November 2009, Dr. Kauffman was Chief Medical Officer of Proteolix Inc., which was acquired by Onyx Pharmaceuticals. At Proteolix, he led the development of Kyprolis® (carfilzomib), a novel proteasome inhibitor approved in refractory myeloma by the Food and Drug Administration in July 2012. Dr. Kauffman was an operating partner at Bessemer Venture Partners from 2006 to 2008, where he led investments in biotechnology companies. From 2006 to 2008, he was President and Chief Executive Officer of Epix Pharmaceuticals, Inc., a biopharmaceutical company that underwent liquidation proceedings through an assignment for the benefit of creditors under Massachusetts law in 2009. Dr. Kauffman was President and Chief Executive Officer of Predix Pharmaceuticals, Inc., a private biopharmaceutical company focused on G protein-coupled receptors (GPCR), from 2002 until its merger into Epix Pharmaceuticals in 2006. In that role, he led the merger of Predix Pharmaceuticals and Epix Pharmaceuticals, oversaw the discovery and development of four new clinical candidates and led collaboration transactions with Amgen and GlaxoSmithKline. From March 2000 to September 2002, Dr. Kauffman was Vice President, Clinical at Millennium Pharmaceuticals, Inc., a biopharmaceutical company, where he led the Velcade® development program.
As the Co-Founder i Chief Executive Officer and Director of Karyopharm Therapeutics Inc, the total compensation of Michael Kauffman at Karyopharm Therapeutics Inc is $3,231,500. There are 1 executives at Karyopharm Therapeutics Inc getting paid more, with Ran Frenkel having the highest compensation of $6,481,860.
Michael Kauffman is 56, he's been the Co-Founder i Chief Executive Officer and Director of Karyopharm Therapeutics Inc since . There are 8 older and 14 younger executives at Karyopharm Therapeutics Inc. The oldest executive at Karyopharm Therapeutics Inc is Garen Bohlin, 72, who is the Independent Director.
Michael's mailing address filed with the SEC is C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 11 years, insiders at Karyopharm Therapeutics Inc have traded over $149,223,596 worth of Karyopharm Therapeutics Inc stock and bought 562,763 units worth $10,312,371 . The most active insiders traders include Deepika Pakianathan, Ltd Czernik Marcin Hadjimic... oraz Mikael Dolsten. On average, Karyopharm Therapeutics Inc executives and independent directors trade stock every 12 days with the average trade being worth of $26,350. The most recent stock trade was executed by Michael Mano on 4 September 2024, trading 3,971 units of KPTI stock currently worth $2,859.
karyopharm therapeutics inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. for more information, please visit www.karyopharm.com
Karyopharm Therapeutics Inc executives and other stock owners filed with the SEC include: